{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:48:05Z","timestamp":1792000085452,"version":"4.4.0"},"reference-count":155,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009527","name":"Statens Serum Institut","doi-asserted-by":"publisher","award":["TB10.4"],"award-info":[{"award-number":["TB10.4"]}],"id":[{"id":"10.13039\/501100009527","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.heliyon.2024.e26193","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:44:36Z","timestamp":1707871476000},"page":"e26193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal"],"prefix":"10.1016","volume":"10","author":[{"given":"Rasoul","family":"Hoseinpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Hasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Abdolalizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Hasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edris","family":"Nabizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Yekani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roqaiyeh","family":"Hasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein Samadi","family":"Kafil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Azizian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0328-4753","authenticated-orcid":false,"given":"Mohammad Yousef","family":"Memar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.heliyon.2024.e26193_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002607","article-title":"Vaccines against tuberculosis: where are we and where do we need to go?","volume":"8","author":"Ottenhoff","year":"2012","journal-title":"PLoS Pathog."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26193_bib2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1586\/erv.12.94","article-title":"Prime\u2013boost approaches to tuberculosis vaccine development","volume":"11","author":"Dalmia","year":"2012","journal-title":"Expet Rev. Vaccine"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(22)00359-7","article-title":"WHO's global tuberculosis report 2022","volume":"4","author":"Bagcchi","year":"2023","journal-title":"The Lancet Microbe"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.immuni.2010.09.015","article-title":"Future vaccination strategies against tuberculosis: thinking outside the box","volume":"33","author":"Kaufmann","year":"2010","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26193_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/2051013615593891","article-title":"Recent advances in the development of vaccines for tuberculosis","volume":"3","author":"Ahsan","year":"2015","journal-title":"Therapeutic advances in vaccines"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26193_bib6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nm.2420","article-title":"A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis","volume":"17","author":"Sweeney","year":"2011","journal-title":"Nature medicine"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26193_bib7","first-page":"1376","volume":"12","author":"Hesseling","year":"2008","journal-title":"Int. J. Tubercul. Lung Dis."},{"issue":"45","key":"10.1016\/j.heliyon.2024.e26193_bib8","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1016\/j.vaccine.2014.07.113","article-title":"Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG)","volume":"32","author":"Copin","year":"2014","journal-title":"Vaccine"},{"issue":"9731","key":"10.1016\/j.heliyon.2024.e26193_bib9","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/S0140-6736(10)60393-5","article-title":"New vaccines for tuberculosis","volume":"375","author":"Kaufmann","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e26193_bib10","first-page":"1331","article-title":"Bacille Calmette-Gu\u00e9rin vaccine-related disease in HIV-infected children: a systematic review","volume":"13","author":"Azzopardi","year":"2009","journal-title":"Int. J. Tubercul. Lung Dis."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26193_bib11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-2249.2006.03222.x","article-title":"The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette\u2013Gu\u00e9rin vaccination in southern England and northern Malawi","volume":"146","author":"Weir","year":"2006","journal-title":"Clin. Exp. Immunol."},{"issue":"22","key":"10.1016\/j.heliyon.2024.e26193_bib12","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.vaccine.2016.03.100","article-title":"Adverse reactions to the Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccine in new-born infants\u2014an evaluation of the Danish strain 1331 SSI in a randomized clinical trial","volume":"34","author":"Nissen","year":"2016","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26193_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MCP.0000000000000041","article-title":"Tuberculosis vaccine development at a divide","volume":"20","author":"Kaufmann","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26193_bib14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1586\/14760584.2013.814836","article-title":"Vaccines against tuberculosis: moving forward with new concepts","volume":"12","author":"Gopal","year":"2013","journal-title":"Expet Rev. Vaccine"},{"issue":"suppl_3","key":"10.1016\/j.heliyon.2024.e26193_bib15","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/cid\/civ609","article-title":"Perspectives on advances in tuberculosis diagnostics, drugs, and vaccines","volume":"61","author":"Schito","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26193_bib16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/mt.2009.60","article-title":"Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis","volume":"17","author":"Mu","year":"2009","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26193_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4161\/hv.8570","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02A: tolerability and immunogenicity in humans","volume":"5","author":"Von Eschen","year":"2009","journal-title":"Hum. Vaccine"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e26193_bib18","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","article-title":"Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial","volume":"31","author":"Leroux-Roels","year":"2013","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.heliyon.2024.e26193_bib19","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26193_bib20","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.tube.2014.07.001","article-title":"Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial","volume":"94","author":"Idoko","year":"2014","journal-title":"Tuberculosis"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e26193_bib21","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.heliyon.2024.e26193_bib22","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"45","key":"10.1016\/j.heliyon.2024.e26193_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013120","article-title":"Long-term safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in HIV-positive and-negative Indian adults: results from a phase II randomized controlled trial","volume":"97","author":"Kumarasamy","year":"2018","journal-title":"Medicine"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e26193_bib24","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMc2001364","article-title":"A trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"382","author":"Ottenhoff","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e26193_bib25","first-page":"1577","article-title":"A trial of M72\/AS01E vaccine to prevent tuberculosis. Reply","volume":"382","author":"Tait","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26193_bib26","doi-asserted-by":"crossref","DOI":"10.4110\/in.2018.18.e17","article-title":"Development of new preventive and therapeutic vaccines for tuberculosis","volume":"18","author":"Kwon","year":"2018","journal-title":"Immune Network"},{"issue":"20","key":"10.1016\/j.heliyon.2024.e26193_bib27","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","article-title":"Ag85B\u2013ESAT-6 adjuvanted with IC31\u00ae promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in na\u00efve human volunteers","volume":"28","author":"van Dissel","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.vaccine.2016.11.023","article-title":"H1: IC31 vaccination is safe and induces long-lived TNF-\u03b1+ IL-2+ CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: a randomized trial","volume":"35","author":"Mearns","year":"2017","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e26193_bib29","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2010.12.135","article-title":"Ag85B\u2013ESAT-6 adjuvanted with IC31\u00ae promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection","volume":"29","author":"Van Dissel","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-017-2354-0","article-title":"A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1\/IC31\u00ae in people living in a TB-endemic area","volume":"19","author":"Hussein","year":"2018","journal-title":"Trials"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26193_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114602","article-title":"Safety and immunogenicity of H1\/IC31\u00ae, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells\/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial","volume":"9","author":"Reither","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26193_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039909","article-title":"The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity","volume":"7","author":"Billeskov","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib33","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.vaccine.2009.10.114","article-title":"Non-clinical efficacy and safety of HyVac4: IC31 vaccine administered in a BCG prime\u2013boost regimen","volume":"28","author":"Skeiky","year":"2010","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.heliyon.2024.e26193_bib34","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.vaccine.2015.05.036","article-title":"The tuberculosis vaccine H4: IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib35","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1080\/21645515.2015.1120393","article-title":"Current status of new tuberculosis vaccine in children","volume":"12","author":"Pang","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2024.e26193_bib36","doi-asserted-by":"crossref","unstructured":"M. Tafaghodi, F. Khademi, Z. Firouzi, Polymer-based Nanoparticles as Delivery Systems for Treatment and Vaccination of Tuberculosis, Nanotechnology Based Approaches for Tuberculosis Treatment, Elsevier2020, pp. 123-142. .","DOI":"10.1016\/B978-0-12-819811-7.00008-4"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26193_bib37","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.vaccine.2017.01.055","article-title":"Safety and immunogenicity of the novel H4: IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: two phase I dose escalation trials","volume":"35","author":"Norrby","year":"2017","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.heliyon.2024.e26193_bib38","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.vaccine.2019.04.035","article-title":"An in vitro functional assay to measure the biological activity of TB vaccine candidate H4-IC31","volume":"37","author":"Ming","year":"2019","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26193_bib39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5114\/ceji.2017.69362","article-title":"Vaccine research and development: tuberculosis as a global health threat","volume":"42","author":"Usman","year":"2017","journal-title":"Cent. Eur. J. Immunol."},{"issue":"33","key":"10.1016\/j.heliyon.2024.e26193_bib40","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Luabeya","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26193_bib41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1164\/rccm.201802-0366OC","article-title":"Dose optimization of H56: IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial","volume":"199","author":"Suliman","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.heliyon.2024.e26193_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100313","article-title":"A phase 1b randomized study of the safety and immunological responses to vaccination with H4: IC31, H56: IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa","volume":"21","author":"Bekker","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"53","key":"10.1016\/j.heliyon.2024.e26193_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001094","article-title":"A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis","volume":"2","author":"Bertholet","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e26193_bib44","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1128\/IAI.02145-14","article-title":"Protection against Mycobacterium leprae infection by the ID83\/GLA-SE and ID93\/GLA-SE vaccines developed for tuberculosis","volume":"82","author":"Duthie","year":"2014","journal-title":"Infect. Immun."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e26193_bib45","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.vaccine.2016.03.029","article-title":"Pulmonary immunity and durable protection induced by the ID93\/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K","volume":"34","author":"Cha","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-52146-0","article-title":"Long-term protective efficacy with a BCG-prime ID93\/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model","volume":"9","author":"Kwon","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26193_bib47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/CVI.00458-15","article-title":"Protection and long-lived immunity induced by the ID93\/GLA-SE vaccine candidate against a clinical Mycobacterium tuberculosis isolate","volume":"23","author":"Baldwin","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-018-0057-5","article-title":"The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial","volume":"3","author":"Coler","year":"2018","journal-title":"npj Vaccines"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib49","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S2213-2600(20)30319-2","article-title":"Safety and immunogenicity of the adjunct therapeutic vaccine ID93+ GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"9","author":"Day","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e26193_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015043","article-title":"Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis","volume":"5","author":"Christensen","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26193_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005771","article-title":"A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells","volume":"4","author":"Kamath","year":"2009","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26193_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/microorganisms7080255","article-title":"Adjuvant strategies for more effective tuberculosis vaccine immunity","volume":"7","author":"Stewart","year":"2019","journal-title":"Microorganisms"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26193_bib54","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.4049\/jimmunol.1300248","article-title":"Control of chronic Mycobacterium tuberculosis infection by CD4 KLRG1\u2212 IL-2\u2013secreting central memory cells","volume":"190","author":"Lindenstr\u00f8m","year":"2013","journal-title":"J. Immunol."},{"issue":"1_Supplement","key":"10.1016\/j.heliyon.2024.e26193_bib55","article-title":"Vaccination with a Hybrid 1 (H1) fusion protein combined with a liposomal adjuvant (CAF01) induced antigen specific T-cells 3 years post vaccination in a human clinical trial.(VAC7P. 971)","volume":"192","author":"Henson","year":"2014","journal-title":"J. Immunol."},{"issue":"52","key":"10.1016\/j.heliyon.2024.e26193_bib56","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"van Dissel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e26193_bib57","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijbiomac.2018.08.037","article-title":"Novel vaccine candidates against Mycobacterium tuberculosis","volume":"120","author":"Khoshnood","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26193_bib58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3892\/br.2016.624","article-title":"Adjunctive therapy of Mycobacterium vaccae vaccine in the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"4","author":"Weng","year":"2016","journal-title":"Biomedical Reports"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26193_bib59","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1128\/CVI.00477-07","article-title":"Mice with pulmonary tuberculosis treated with Mycobacterium vaccae develop strikingly enhanced recall gamma interferon responses to M. vaccae cell wall skeleton","volume":"15","author":"Rodr\u00edguez-Guell","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e26193_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023826","article-title":"Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e26193_bib61","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1080\/21645515.2017.1335374","article-title":"Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: a systematic review and meta-analysis","volume":"13","author":"Huang","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2024.e26193_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jctube.2019.100141","article-title":"Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month","volume":"18","author":"Bourinbaiar","year":"2020","journal-title":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26193_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175215","article-title":"Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901","volume":"12","author":"von Reyn","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26193_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168521","article-title":"Immunogenicity and protective efficacy of the DAR-901 booster vaccine in a murine model of tuberculosis","volume":"11","author":"Lahey","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26193_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217091","article-title":"CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: a randomized, placebo-controlled trial","volume":"14","author":"Masonou","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26193_bib66","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-3083.2008.02103.x","article-title":"The tuberculin skin test increases the responses measured by T cell interferon\u2010gamma release assays","volume":"67","author":"Vilaplana","year":"2008","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e26193_bib67","series-title":"IEEE International Conference on Bioinformatics and Biomedicine (BIBM)","first-page":"2197","article-title":"Evaluation of the efficacy of RUTI and ID93\/GLA-SE vaccines in tuberculosis treatment: in silico trial through UISS-TB simulator","author":"Russo","year":"2019"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26193_bib68","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1128\/CVI.00094-08","article-title":"Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and Guinea pig experimental models of tuberculosis","volume":"15","author":"Guirado","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.heliyon.2024.e26193_bib69","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3389\/fimmu.2019.00894","article-title":"RUTI vaccination enhances inhibition of mycobacterial growth ex vivo and induces a shift of monocyte phenotype in mice","volume":"10","author":"Prabowo","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26193_bib70","doi-asserted-by":"crossref","first-page":"127","DOI":"10.47276\/lr.76.2.127","article-title":"Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8\u201310 years","volume":"76","author":"Sharma","year":"2005","journal-title":"Lepr. Rev."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26193_bib71","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.3390\/app10072632","article-title":"Update on TB vaccine pipeline","volume":"10","author":"Martin","year":"2020","journal-title":"Appl. Sci."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib72","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijtb.2018.08.004","article-title":"Potential of adjunctive Mycobacterium w (MIP) immunotherapy in reducing the duration of standard chemotherapy against tuberculosis","volume":"65","author":"Chahar","year":"2018","journal-title":"Indian J. Tubercul."},{"key":"10.1016\/j.heliyon.2024.e26193_bib73","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.tube.2016.09.027","article-title":"Mycobacterium indicus pranii (MIP) mediated host protective intracellular mechanisms against tuberculosis infection: involvement of TLR-4 mediated signaling","volume":"101","author":"Das","year":"2016","journal-title":"Tuberculosis"},{"key":"10.1016\/j.heliyon.2024.e26193_bib74","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tube.2016.10.002","article-title":"Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis","volume":"101","author":"Saqib","year":"2016","journal-title":"Tuberculosis"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-019-4157-2","article-title":"Aerosol immunization by alginate coated mycobacterium (BCG\/MIP) particles provide enhanced immune response and protective efficacy than aerosol of plain mycobacterium against M. tb. H37Rv infection in mice","volume":"19","author":"Nagpal","year":"2019","journal-title":"BMC Infect. Dis."},{"issue":"42","key":"10.1016\/j.heliyon.2024.e26193_bib76","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26193_bib77","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14760584.2017.1324303","article-title":"MTBVAC from discovery to clinical trials in tuberculosis-endemic countries","volume":"16","author":"Marinova","year":"2017","journal-title":"Expet Rev. Vaccine"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2020.100185","article-title":"Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination","volume":"2","author":"Vierboom","year":"2021","journal-title":"Cell Reports Medicine"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008404","article-title":"New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia","volume":"16","author":"Taranc\u00f3n","year":"2020","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-020-00262-8","article-title":"MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies","volume":"6","author":"White","year":"2021","journal-title":"npj Vaccines"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib81","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mjafi.2018.12.013","article-title":"Current trends in tuberculosis vaccine","volume":"75","author":"Soundarya","year":"2019","journal-title":"Med. J. Armed Forces India"},{"key":"10.1016\/j.heliyon.2024.e26193_bib82","series-title":"A New Intranasal Influenza Vector-Based Vaccine TB\/FLU-04L against Tuberculosis: Preclinical Safety Studies","author":"Buzitskaya","year":"2022"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26193_bib83","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/eji.201444954","article-title":"Epitope\u2010specific CD4+, but not CD8+, T\u2010cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection","volume":"45","author":"Fl\u00f3rido","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e26193_bib84","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3390\/vaccines9111273","article-title":"Enhancement of the local CD8+ T-cellular immune response to Mycobacterium tuberculosis in BCG-primed mice after intranasal administration of influenza vector vaccine carrying TB10. 4 and HspX antigens","volume":"9","author":"Vasilyev","year":"2021","journal-title":"Vaccines"},{"issue":"9871","key":"10.1016\/j.heliyon.2024.e26193_bib85","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26193_bib86","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S2213-2600(15)00037-5","article-title":"Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial","volume":"3","author":"Ndiaye","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib87","first-page":"1","article-title":"Vaccine against tuberculosis: what's new?","volume":"14","author":"Montagnani","year":"2014","journal-title":"BMC Infect. Dis."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26193_bib88","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","article-title":"Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial","volume":"14","author":"Satti","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e26193_bib89","article-title":"Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine","volume":"3","author":"Wajja","year":"2018","journal-title":"MVA85A, Wellcome open research"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26193_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005440","article-title":"The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: an open-label trial","volume":"11","author":"Wajja","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002790","article-title":"Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial","volume":"16","author":"Manjaly Thomas","year":"2019","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib92","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/cid\/cix834","article-title":"Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed bacille calmette-guerin for infants of human immunodeficiency virus-infected mothers: a phase 2 randomized, controlled trial","volume":"66","author":"Nemes","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib93","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/sji.12465","article-title":"Global efforts in the development of vaccines for tuberculosis: requirements for improved vaccines against Mycobacterium tuberculosis","volume":"84","author":"M\u00e9ndez\u2010Samperio","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e26193_bib94","series-title":"Safety and Immunogenicity of the Ad35\/AERAS-402 Tuberculosis Vaccine in a Phase 2 Dose-Finding Clinical Trial in BCG-Vaccinated Healthy Infants (VAC5P. 1119)","author":"Hokey","year":"2015"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e26193_bib95","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.vaccine.2016.03.069","article-title":"Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON\u00ae-TB Gold (+) Kenyan adults without evidence of tuberculosis","volume":"34","author":"Walsh","year":"2016","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.heliyon.2024.e26193_bib96","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.vaccine.2015.02.004","article-title":"The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts> 350 cells\/mm3","volume":"33","author":"Churchyard","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep36355","article-title":"Adenovirally-induced polyfunctional T cells do not necessarily recognize the infected target: lessons from a phase I trial of the AERAS-402 vaccine","volume":"6","author":"Nyendak","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e26193_bib98","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201603-0654OC","article-title":"Safety and immunogenicity of adenovirus 35 tuberculosis vaccine candidate in adults with active or previous tuberculosis. A randomized trial","volume":"195","author":"van Zyl-Smit","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26193_bib99","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.4049\/jimmunol.173.10.6357","article-title":"Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis","volume":"173","author":"Wang","year":"2004","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26193_bib100","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.4049\/jimmunol.181.7.4955","article-title":"Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice","volume":"181","author":"Forbes","year":"2008","journal-title":"J. Immunol."},{"issue":"44","key":"10.1016\/j.heliyon.2024.e26193_bib101","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1016\/j.vaccine.2012.07.086","article-title":"Immunogenicity comparison of the intradermal or endobronchial boosting of BCG vaccinates with Ad5-85A","volume":"30","author":"Whelan","year":"2012","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.heliyon.2024.e26193_bib102","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.vaccine.2018.03.068","article-title":"Ag85A-specific CD4+ T cell lines derived after boosting BCG-vaccinated cattle with Ad5-85A possess both mycobacterial growth inhibition and anti-inflammatory properties","volume":"36","author":"Metcalfe","year":"2018","journal-title":"Vaccine"},{"issue":"205","key":"10.1016\/j.heliyon.2024.e26193_bib103","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus\u2013based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e26193_bib104","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijid.2014.11.026","article-title":"Tuberculosis Vaccines\u2013state of the art, and novel approaches to vaccine development","volume":"32","author":"da Costa","year":"2015","journal-title":"Int. J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.vaccine.2019.10.102","article-title":"A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime\u2013MVA85A boost in healthy UK adults","volume":"38","author":"Wilkie","year":"2020","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26193_bib106","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/14760584.2014.905746","article-title":"The BCG replacement vaccine VPM1002: from drawing board to clinical trial","volume":"13","author":"Kaufmann","year":"2014","journal-title":"Expet Rev. Vaccine"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e26193_bib107","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","article-title":"Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial","volume":"31","author":"Grode","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26193_bib108","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00439-16","article-title":"Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa","volume":"24","author":"Loxton","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26193_bib109","doi-asserted-by":"crossref","first-page":"A46","DOI":"10.1055\/s-0033-1363139","article-title":"VPM1002: a new TB prime vaccine on the horizon","volume":"68","author":"Minhas","year":"2014","journal-title":"Pneumologie"},{"key":"10.1016\/j.heliyon.2024.e26193_bib110","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","article-title":"The recombinant Bacille Calmette\u2013Gu\u00e9rin vaccine VPM1002: ready for clinical efficacy testing","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26193_bib111","doi-asserted-by":"crossref","first-page":"12530","DOI":"10.1002\/jcp.28120","article-title":"Nanovaccine: a novel approach in immunization","volume":"234","author":"Gheibi Hayat","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26193_bib112","article-title":"Improving cancer vaccine efficiency by nanomedicine","volume":"3","author":"Cai","year":"2019","journal-title":"Advanced Biosystems"},{"key":"10.1016\/j.heliyon.2024.e26193_bib113","doi-asserted-by":"crossref","unstructured":"R. Ojha, R.K. Pandey, V.K. Prajapati, Vaccine Delivery Systems against Tuberculosis, Nanotechnology Based Approaches for Tuberculosis Treatment, Elsevier2020, pp. 75-90.","DOI":"10.1016\/B978-0-12-819811-7.00005-9"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26193_bib114","first-page":"291","article-title":"Development of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen, Artificial cells","volume":"45","author":"Amini","year":"2017","journal-title":"nanomedicine, and biotechnology"},{"issue":"13\u201314","key":"10.1016\/j.heliyon.2024.e26193_bib115","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.vaccine.2003.09.044","article-title":"Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A* 0201-restricted T-cell epitopes of Mycobacterium tuberculosis","volume":"22","author":"Bivas-Benita","year":"2004","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e26193_bib116","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/aa60fd","article-title":"Biocompatible chitosan nanoparticles as an efficient delivery vehicle for Mycobacterium tuberculosis lipids to induce potent cytokines and antibody response through activation of \u03b3\u03b4 T cells in mice","volume":"28","author":"Das","year":"2017","journal-title":"Nanotechnology"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib117","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/erm.09.15","article-title":"Current advances in research and clinical applications of PLGA-based nanotechnology","volume":"9","author":"L\u00fc","year":"2009","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26193_bib118","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0169-409X(02)00228-4","article-title":"Biodegradable nanoparticles for drug and gene delivery to cells and tissue","volume":"55","author":"Panyam","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"30","key":"10.1016\/j.heliyon.2024.e26193_bib119","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1016\/j.vaccine.2009.04.033","article-title":"Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA\u2013PEI nanoparticles enhances T cell responses in a DNA prime\/protein boost vaccination regimen in mice","volume":"27","author":"Bivas-Benita","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e26193_bib120","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.micpath.2018.10.023","article-title":"A novel antigen of Mycobacterium tuberculosis and MPLA adjuvant co-entrapped into PLGA: DDA hybrid nanoparticles stimulates mucosal and systemic immunity","volume":"125","author":"Khademi","year":"2018","journal-title":"Microb. Pathog."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26193_bib121","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.nano.2012.02.015","article-title":"Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection","volume":"8","author":"Yu","year":"2012","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"40","key":"10.1016\/j.heliyon.2024.e26193_bib122","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2011.07.039","article-title":"Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis","volume":"29","author":"Ballester","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26193_bib123","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3109\/10717544.2014.894594","article-title":"Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis","volume":"22","author":"Kaur","year":"2015","journal-title":"Drug Deliv."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26193_bib124","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/pharmaceutics12121218","article-title":"Mesoporous silica nanoparticles as a potential platform for vaccine development against tuberculosis","volume":"12","author":"Montalvo-Quir\u00f3s","year":"2020","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26193_bib125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/17425247.2012.666968","article-title":"Liposomes in cosmeceutics","volume":"9","author":"Rahimpour","year":"2012","journal-title":"Expet Opin. Drug Deliv."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e26193_bib126","doi-asserted-by":"crossref","first-page":"e3116","DOI":"10.1371\/journal.pone.0003116","article-title":"Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements","volume":"3","author":"Agger","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e26193_bib127","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3389\/fimmu.2019.01349","article-title":"Immunization with Mycobacterium tuberculosis antigens encapsulated in phosphatidylserine liposomes improves protection afforded by BCG","volume":"10","author":"Diogo","year":"2019","journal-title":"Front. Immunol."},{"issue":"3\u20134","key":"10.1016\/j.heliyon.2024.e26193_bib128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tube.2006.01.024","article-title":"RUTI: a new chance to shorten the treatment of latent tuberculosis infection","volume":"86","author":"Cardona","year":"2006","journal-title":"Tuberculosis"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26193_bib129","first-page":"156","article-title":"Increasing cellular immune response in liposomal formulations of DOTAP encapsulated by fusion protein Hspx, PPE44, and Esxv, as a potential tuberculosis vaccine candidate","volume":"7","author":"Mansury","year":"2019","journal-title":"Reports of Biochemistry & Molecular Biology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26193_bib130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032959","article-title":"Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis","volume":"7","author":"Derrick","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e26193_bib131","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fimmu.2018.00310","article-title":"Formulation in DDA-MPLA-TDB liposome enhances the immunogenicity and protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection","volume":"9","author":"Tian","year":"2018","journal-title":"Front. Immunol."},{"issue":"34","key":"10.1016\/j.heliyon.2024.e26193_bib132","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1016\/j.vaccine.2014.06.037","article-title":"Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection","volume":"32","author":"Trentini","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib133","first-page":"370","article-title":"Enhancement of the effect of BCG vaccine against tuberculosis using DDA\/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV, Artificial Cells","volume":"47","author":"Mansury","year":"2019","journal-title":"Nanomedicine, and Biotechnology"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib134","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12033-012-9598-4","article-title":"Construction and characterization of virus-like particles: a review","volume":"53","author":"Zeltins","year":"2013","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.heliyon.2024.e26193_bib135","first-page":"835","article-title":"Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles","volume":"8","author":"Dhanasooraj","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.heliyon.2024.e26193_bib136","doi-asserted-by":"crossref","unstructured":"D. Dhanasooraj, R.A. Kumar, S. Mundayoor, Subunit Protein Vaccine Delivery System for Tuberculosis Based on Hepatitis B Virus Core VLP (HBc-VLP) Particles, Vaccine Design, Springer2016, pp. 377-392.","DOI":"10.1007\/978-1-4939-3389-1_26"},{"key":"10.1016\/j.heliyon.2024.e26193_bib137","first-page":"835","article-title":"Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles","author":"Dhanasooraj","year":"2013","journal-title":"Int. J. Nanomed."},{"issue":"34","key":"10.1016\/j.heliyon.2024.e26193_bib138","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1016\/j.vaccine.2011.06.012","article-title":"Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses","volume":"29","author":"Yin","year":"2011","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26193_bib139","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.3390\/v15102123","article-title":"Nano-sized chimeric human papillomavirus-16 L1 virus-like particles displaying mycobacterium tuberculosis antigen Ag85B enhance Ag85B-specific immune responses in female C57BL\/c mice","volume":"15","author":"Zhou","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jviromet.2010.03.003","article-title":"Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis","volume":"167","author":"Krammer","year":"2010","journal-title":"J. Virol Methods"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26193_bib141","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3390\/vaccines11050941","article-title":"A VLP-based vaccine displaying HBHA and MTP antigens of Mycobacterium tuberculosis induces protective immune responses in M. tuberculosis H37Ra infected mice","volume":"11","author":"Wang","year":"2023","journal-title":"Vaccines"},{"issue":"51","key":"10.1016\/j.heliyon.2024.e26193_bib142","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1016\/j.vaccine.2015.10.124","article-title":"Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26193_bib143","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1515\/acph-2015-0019","article-title":"Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment","volume":"65","author":"Liu","year":"2015","journal-title":"Acta Pharm."},{"key":"10.1016\/j.heliyon.2024.e26193_bib144","series-title":"Immunogenic Responses by Tuberculosis Vaccination with Sendai-Virosomal pDNA Encoding mAg85A","author":"\uc1a1\uc778\ud638","year":"2007"},{"issue":"33","key":"10.1016\/j.heliyon.2024.e26193_bib145","first-page":"4388","volume":"27","author":"Sun","year":"2009","journal-title":"ISCOMs and ISCOMATRIX\u2122, Vaccine"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26193_bib146","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3109\/21691401.2014.966195","article-title":"Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes","volume":"44","author":"Pabreja","year":"2016","journal-title":"Artif. Cell Nanomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib147","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1128\/IAI.01290-06","article-title":"The combined CTA1-DD\/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to","volume":"75","author":"Andersen","year":"2007","journal-title":"Mycobacterium tuberculosis, Infection and immunity"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib148","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0264-410X(00)00102-X","article-title":"Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis","volume":"19","author":"Da Fonseca","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e26193_bib149","article-title":"Immunogenicity of HspX\/EsxS fusion protein of Mycobacterium tuberculosis along with ISCOMATRIX and PLUSCOM nano-adjuvants after subcutaneous administration in animal model","volume":"154","author":"Avarvand","year":"2021","journal-title":"Microb. Pathog."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26193_bib150","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/ph16101428","article-title":"Functionalizing dendrimers for targeted delivery of bioactive molecules to macrophages: a potential treatment for Mycobacterium tuberculosis infection\u2014a review","volume":"16","author":"Sanhueza","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26193_bib151","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/pharmaceutics3030458","article-title":"Fourth generation phosphorus-containing dendrimers: prospective drug and gene delivery carrier","volume":"3","author":"Shcharbin","year":"2011","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26193_bib152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1556-276X-9-247","article-title":"Dendrimers: synthesis, applications, and properties","volume":"9","author":"Abbasi","year":"2014","journal-title":"Nanoscale Res. Lett."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26193_bib153","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2174\/1567201816666190123120915","article-title":"Cell-penetrating peptides: efficient vectors for vaccine delivery","volume":"16","author":"Yang","year":"2019","journal-title":"Curr. Drug Deliv."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26193_bib154","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1021\/bm034051a","article-title":"Synthesis and properties of star-shaped polylactide attached to poly (amidoamine) dendrimer","volume":"4","author":"Cai","year":"2003","journal-title":"Biomacromolecules"},{"issue":"3\u20134","key":"10.1016\/j.heliyon.2024.e26193_bib155","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1389-0352(01)00061-7","article-title":"Peptide dendrimers: applications and synthesis","volume":"90","author":"Sadler","year":"2002","journal-title":"Rev. Mol. Biotechnol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024022242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024022242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:19:43Z","timestamp":1790713183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024022242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":155,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2405844024022242"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26193","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e26193"}}